Citations

Showing 10 of 108162 citations.

Congenital Heart Disease and the Liver
Hilscher, Moira , Kamath, Patrick S. , Hilscher, Moira B

Mayo Clinic

Clinical Liver Disease | November 6, 2019 | Volume: 14 | Issue: 4 | Pages: 138-141

10.1002/cld.828 | PMID 31709041 Get It

The Ethics of Informed Consent for Psychotherapy
McKean, Alastair J. , Trachsel, Manuel , Croarkin, Paul E.

Mayo Clinic

Oxford Handbook of Psychotherapy Ethics | November 6, 2019 | Volume: No volume available | Issue: No issue available | Pages: 258-270

10.1093/oxfordhb/9780198817338.013.23 Get It

Abstract Informed consent, enshrined in many of the codes of conduct of psychology and psychiatry professional organizations, is an integral component behind the ethical practice of psychotherapy. Foundationally, informed consent respects patient autonomy and should be a knowledge sharing process that allows patients greater agency and improved alliance with their clinician. Psychotherapy differs from medical and surgical interventions in that it is a longitudinal, collaborative, and interpersonal treatment. As many psychotherapists are not trained in traditional medical models of care, a medically based framework for informed consent may not be as familiar and appropriate for psychotherapy. These nuances do not diminish the need for informed consent but rather emphasize the distinctiveness of psychotherapy and necessity of adapting to this treatment modality. In this chapter, the informed consent process for psychotherapy is examined, detailing its historical development, legal and ethical foundations, as well as the subtleties and challenges regarding implementation.
AGA Clinical Practice Update on Surgical Risk Assessment and Perioperative Management in Cirrhosis: Expert Review
Northup, Patrick G. , Friedman, Lawrence S., Kamath, Patrick S.

Mayo Clinic

Clinical Liver Disease | November 6, 2019 | Volume: 14 | Issue: 4 | Pages: 135-137

10.1002/cld.875 Get It

Association between allelic variants in the glucagon‐like peptide 1 and cholecystokinin receptor genes with gastric emptying and glucose tolerance
Anderson, Bradley J. , Carlson, Paula, LAURENTI, MARCELLO C. , Camilleri, Michael , Desai, Anshuman, Feuerhak, Kelly, Bharucha, Adil E. , Anderson, Bradley, Laurenti, Marcello, Camilleri, M , Bharucha, A E , Vella, Adrian

Mayo Clinic

Neurogastroenterology & Motility | November 6, 2019 | Volume: 32 | Issue: 1 | Pages: No page available

10.1111/nmo.13724 | PMID 31691451 Get It

AbstractBackgroundNutrient‐mediated release of cholecystokinin and glucagon‐like peptide‐1 (GLP‐1) regulates gastric emptying (GE) via duodenogastric feedback mechanisms; GLP‐1 also regulates postprandial insulin secretion. Some patients with functional upper gastrointestinal symptoms have impaired glucose tolerance during enteral dextrose infusion. Our hypothesis was that variants in CCK, GLP‐1, and TCF7L2 (transcription factor 7‐like 2 locus), which is associated with greatest genetic risk for development of type 2 diabetes mellitus, are associated with GE and independently with glucose tolerance. Our aims were to evaluate the associations between these GE, glucose tolerance, and these single nucleotide polymorphisms (SNPs).MethodsGenetic variants, scintigraphic GE of solids, plasma glucose, insulin, and GLP‐1 during enteral dextrose infusion (75gm over 2 hours) were measured. GE and enteral dextrose infusion were, respectively, evaluated in 44 (27 controls and 17 patients with functional dyspepsia or nausea) and 42 (28 controls, 14 patients) participants; of these, 51 participants consented to assessment of SNPs. Four functional SNPs were studied: rs6923761 and rs1042044 at GLP‐1 receptor, rs7903146 (TCF7L2), and rs1800857 (CCK receptor).Key ResultsGastric emptying was normal in 38, rapid in 4, and delayed in two participants; 38 had normal, and four had impaired glucose tolerance. The T allele at rs7903146 (TCF7L2) was non‐significantly associated (P = .14) with faster GE. The associations between SNPs and demographic variables, GE thalf, glucose tolerance and plasma GLP1 levels were not significant.Conclusions & InferencesThere is a trend toward an association between faster GE and the diabetes‐associated allele at rs7903146 in TCF7L2. However, these SNPs were not associated with plasma glucose or GLP1 concentrations during enteral dextrose infusion.
The Effectiveness of a Non-Invasive Shot Blocking Device for Reducing Pain of In-office Injections in Hand Surgery
Rinker, Brian, Atashroo, David, Wermeling, F. Ryan, Rinker, Brian D , Stout, Megan A.

Mayo Clinic

HAND | November 6, 2019 | Volume: 16 | Issue: 6 | Pages: 770-775

10.1177/1558944719884655 | PMID 31690117 Get It

Background: The gate control theory asserts that non-painful stimuli can block pain perception. The ShotBlocker™ device is a plastic disk with blunt projections that rests on the skin, and we hypothesize that it will reduce pain during hand injections. Methods: This is a prospective randomized trial of 117 patients undergoing injections for common hand conditions. Patients were randomized into 3 groups: device, placebo (device with projections removed), and control. Patients recorded on an analog pain scale the pain severity of the injection, as well as their most recent tetanus shot. A normalized pain score was obtained from the difference between the injection and tetanus shot pain scores. The mean non-normalized and normalized scores for each treatment group were compared to the control group using the Wilcoxon signed rank test. Results: There were 91 women and 26 men. Common diagnoses included trigger finger (n = 53), DeQuervain’s tendonitis (n = 33), and basal joint arthritis (n = 22). The groups did not differ significantly in age, gender, or diagnosis. Mean pain score in the device group was 5.2 out of 10, and it was 5.7 for the control group. The normalized pain score in the device group was significantly lower than the control group. Normalized and non-normalized pain scores for the placebo group were not significantly lower than the control group. Conclusions: The shot blocking device effectively reduced pain of injection versus controls when pain scores were normalized for pain tolerance. The modified device did not reduce the pain of injection, suggesting that gate control is the mechanism of action.
Current Evidence Lacking to Guide Clinical Practice for Spinal Cord Stimulation in the Treatment of Neuropathic Pain in Spinal Cord Injury: A Review of the Literature and a Proposal for Future Study
Dombovy‐Johnson, Marissa L. , Morrow, Melissa M. , Lamer, Tim J. , Pittelkow, Thomas P. , Hunt, Christine L., Morrow, Melissa M , Lamer, Tim J , Pittelkow, Thomas P , Hunt, Christine

Mayo Clinic

Pain Practice | November 6, 2019 | Volume: 20 | Issue: 3 | Pages: 325-335

10.1111/papr.12855 | PMID 31691496 Get It

Abstract Background/Objective Chronic pain is commonly reported in individuals with spinal cord injuries (SCIs), with recent prevalence reported as high as 80%. Uncontrolled pain is known to decrease quality of life, attenuate mood, and impact sleep. Spinal cord stimulation (SCS) for the treatment of refractory pain was first used in the SCI population in 1972. To date there have been no randomized controlled trials examining the effect of SCS on neuropathic pain post‐SCI. A literature review in 2009 identified 27 studies, the majority prior to 2000, that included at least 1 patient with SCI. Given the significant advancements in the field of SCS, this review examines the updated evidence of SCS for the treatment of neuropathic pain in individuals with SCI and provides guidance on future investigations. Methods MEDLINE and EMBASE databases were searched. All published reports, case series, and clinical trials reviewing SCS for neuropathic pain that included at least 1 individual with SCI were included. Results The initial search identified 376 reports, of which 22 met inclusion criteria, for a total of 69 patients. All reports were of very low quality. A majority of the reported patients were male, underwent tonic stimulation, and reportedly experienced improvement in pain and spasticity, with decreased use of pain medication. Conclusions The synthesized findings from primarily case studies support the safety of SCS in SCI with the suggestion of potential pain relief benefit; however, data from low‐quality studies are insufficient for informing clinical practice. A well‐designed, prospective clinical trial is proposed to further investigate this indication.
Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: Is there still a role for desensitization?
Schinstock, Carrie A. , Smith, Byron H. , Bentall, Andrew , Mai, Martin, Khamash, Hasan , Stegall, Mark D. , Khamash, Hasan A, Stegall, Mark D , Smith, Byron , Schinstock, Carrie , Bentall, Andrew , Montgomery, Robert A. , Jordan, Stanley C.

Mayo Clinic

Clinical Transplantation | November 5, 2019 | Volume: 33 | Issue: 12 | Pages: No page available

10.1111/ctr.13751 | PMID 31769104 Get It

AbstractKidney paired donation (KPD) and the new kidney allocation system (KAS) in the United States have led to improved transplantation rates for highly sensitized candidates. We aimed to assess the potential need for other approaches to improve the transplantation rate of highly sensitized candidates such as desensitization. Using the UNOS STAR file, we analyzed transplant rates in a prevalent active waiting‐list cohort as of June 1, 2016, followed for 1 year. The overall transplantation rate was 18.9% (11 129/58769). However, only 9.7% (213/2204) of candidates with a calculated panel reactive antibody ≥99.9% received a transplant, and highly sensitized candidates were less likely to receive a living donor transplant. Among candidates with a CPRA ≥ 99.5% (ie. 100%), only 2.5% of transplants were from living donors (13 total, 7 from KPD). Nearly 4 years after KAS (6/30/2018), 1791 actively wait‐listed candidates had a CPRA of ≥99.9% and 34.6% (620/1791) of these had ≥5 years of waiting time. Thus, despite KPD and KAS, many sensitized candidates have not been transplanted even with prolonged waiting time. We conclude that candidates with a CPRA ≥ 99.9% and sensitized candidates with an incompatible living donor and prolonged waiting time may benefit from desensitization to improve their ability to receive a transplant.
ABCA7 haplodeficiency disturbs microglial immune responses in the mouse brain
Aikawa, Tomonori , Ren, Yingxue , Tachibana, Masaya , Johnson, Madeleine R., Anderson, Casey T., Martens, Yuka A. , Holm, Marie‐Louise , Asmann, Yan W. , Saito, Takashi , Fitzgerald, Michael L. , Bu, Guojun , Kanekiyo, Takahisa , Bu, Guojun , Aikawa, Tomonori , Yamazaki, Yu , Saido, Takaomi C.

Mayo Clinic

Proceedings of the National Academy of Sciences | November 5, 2019 | Volume: 116 | Issue: 47 | Pages: 23790-23796

10.1073/pnas.1908529116 | PMID 31690660 Get It

Carrying premature termination codons in 1 allele of the ABCA7 gene is associated with an increased risk for Alzheimer’s disease (AD). While the primary function of ABCA7 is to regulate the transport of phospholipids and cholesterol, ABCA7 is also involved in maintaining homeostasis of the immune system. Since inflammatory pathways causatively or consequently participate in AD pathogenesis, we studied the effects of Abca7 haplodeficiency in mice on brain immune responses under acute and chronic conditions. When acute inflammation was induced through peripheral lipopolysaccharide injection in control or heterozygous Abca7 knockout mice, partial ABCA7 deficiency diminished proinflammatory responses by impairing CD14 expression in the brain. On breeding to App NL-G-F knockin mice, we observed increased amyloid-β (Aβ) accumulation and abnormal endosomal morphology in microglia. Taken together, our results demonstrate that ABCA7 loss of function may contribute to AD pathogenesis by altering proper microglial responses to acute inflammatory challenges and during the development of amyloid pathology, providing insight into disease mechanisms and possible treatment strategies.
Multiparametric Magnetic Resonance Elastography Improves the Detection of NASH Regression Following Bariatric Surgery
Allen, Alina M. , Shah, Vijay H. , Therneau, Terry M. , Venkatesh, Sudhakar K. , Mounajjed, Taofic, Larson, Joseph J. , Mara, Kristin C. , Kellogg, Todd A., Kendrick, Michael L. , McKenzie, Travis J. , Greiner, Suzanne , Li, Jiahui , Glaser, Kevin J. , Wells, Michael , Gunneson, Timothy J., Yin, Meng , Greiner, Suzanne M, Wells, Michael L, Venkatesh, Sudhakar K , Mara, Kristin C , Allen, Alina M , Yin, Meng , Li, Jiahui , Ehman, Richard L.

Mayo Clinic

Hepatology Communications | November 5, 2019 | Volume: 4 | Issue: 2 | Pages: 185-192

10.1002/hep4.1446 | PMID 32025604 Get It

Disease monitoring in nonalcoholic steatohepatitis (NASH) is limited by absence of noninvasive biomarkers of disease regression or progression. We aimed to examine the role of multiparametric three‐dimensional magnetic resonance elastography (3D‐MRE) and magnetic resonance imaging proton density fat fraction (MRI‐PDFF) in the detection of NASH regression after interventions. This is a single‐center prospective clinical trial of 40 patients who underwent bariatric surgery. Imaging and liver biopsies were obtained at baseline and 1 year after surgery. The imaging protocol consisted of multifrequency 3D‐MRE to determine the shear stiffness at 60 Hz and damping ratio at 40 Hz, and MRI‐PDFF to measure the fat fraction. A logistic regression model including these three parameters was previously found to correlate with NASH. We assessed the model performance in the detection of NASH resolution after surgery by comparing the image‐predicted change in NAFLD activity score (delta NAS) to the histologic changes. A total of 38 patients (median age 43, 87% female, 30 of 38 with NAS ≥ 1, and 13 of 38 with NASH) had complete data at 1 year. The NAS decreased in all subjects with NAS ≥ 1 at index biopsy, and NASH resolved in all 13. There was a strong correlation between the predicted delta NAS by imaging and the delta NAS by histology (r = 0.73, P < 0.001). The strength of correlation between histology and the predicted delta NAS using single conventional parameters, such as the fat fraction by MRI‐PDFF or shear stiffness at 60 Hz by MRE, was r = 0.69 (P < 0.001) and r = 0.43 (P = 0.009), respectively. Conclusion: Multiparametric 3D‐MRE and MRI‐PDFF can detect histologic changes of NASH resolution after bariatric surgery. Studies in a nonbariatric setting are needed to confirm the performance as a composite noninvasive biomarker for longitudinal NASH monitoring.